no reporting requirement [6, 9, 10] , and babesiosis, unlike Lyme disease, is not nationally notifiable. Infected patients can harbor circulating parasites for months or years without symptoms; patients with chronic low-level parasitemia may unknowingly transmit the organisms through donating blood [7, 8] . There is no licensed test for Babesia screening of donated blood products.
The majority of an estimated 70 transfusion-transmitted Babesia infections since 1979 involved B. microti; most of these infections were reported in the past decade (D. Leiby, personal communication) [7] . The national standard blood donor questionnaire includes questions about prior babesiosis infection and general donor health [11] . Individuals with previously diagnosed babesiosis are indefinitely deferred (ineligible to donate blood). However, mild Babesia infections may remain unrecognized, and infected individuals may not recall recent tick bites [12] .
The purpose of this article is to alert clinicians and the public health community of reported deaths related to transfusiontransmitted babesiosis; to describe the US Food and Drug Administration's (FDA's) surveillance systems for adverse events and product manufacturing deviations related to donor blood collection, distribution, and transfusion; and to encourage the reporting of suspected cases of transfusion-transmitted babesiosis.
METHODS
The FDA's surveillance systems. The FDA receives information about suspected complications of blood collection and transfusion via the 3 following systems: fatality reports for blood donors and transfusion recipients, the Adverse Event Reporting System (AERS; which includes the FDA MedWatch program), and the Biological Product Deviations Reporting (BPDR) system (table 1) .
Blood establishments are required to notify the FDA "when a complication of blood collection or transfusion is confirmed to be fatal" [13, p. 58] . Center for Biologics Evaluation and Research medical officers review documentation from the reporting facility and reports from FDA investigators to assess the relationship, if any, to the blood donation or transfusion.
Biologics manufacturers are required to submit reports of adverse experiences to the AERS, the FDA's computerized database for postmarketing safety surveillance. The voluntary MedWatch program allows health care professionals and consumers to report adverse events to the AERS. The FDA's BPDR system receives reports of "any event…associated with the manufacturing, to include testing, processing, packing, labeling, or storage, or with the holding or distribution of a licensed biological product or blood or blood components … in which the safety, purity, or potency of a distributed product may be affected" [14] .
Data query. We queried these systems for babesiosisrelated blood donation or transfusion events reported from 1 October 1996 (FDA fiscal year 1997) through 31 December 2007 (first quarter of fiscal year 2008). We analyzed fatality reports for time frames, clinical presentations, and patient and donor demographic characteristics. Babesiosis-related reports to the BPDR system typically describe either possible transfusion-transmitted disease or postdonation illness, with potential implications for the safety of the donated blood units. We categorized cases reported to the BPDR system as postdonation illness and potential transfusion transmission-related events. To avoid distortion of BPDR trends, we excluded reports of infected donors identified prospectively through antibody assay research [7] . (table 2) were consistent with natural tick-borne Babesia infection in asplenic, immunocompromised, or other patients with serious comorbid chronic disease [12] . All were infected with B. microti and had received RBCs; 1 death was attributable to a unit of frozen deglycerolized RBCs. Recipients developed symptoms in 2.5-7 weeks and died within 2 months after transfusion of the implicated blood units (table 3) . FDA medical review verified that transfusion-transmitted babesiosis contributed to each death.
RESULTS
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BPDR. Figure 1 AERS. Since 1997, the AERS has not received any report of transfusion-transmitted babesiosis.
Laboratory and blood establishment investigations. All fatal cases (in blood recipients) reported here were initially diagnosed with use of a thin peripheral blood smear. For each fatality, subsequent donor testing by immunofluorescence antibody assay revealed elevated B. microti antibody titers (у1: 128). All implicated donors were indefinitely deferred from donating blood.
DISCUSSION
Babesiosis has gained attention as an emerging zoonotic disease with an expanding known geographical range [6, 9, 15, 16] . Since November 2005, the FDA learned of 8 deaths involving transfusion-transmitted babesiosis and has received increasing reports of nonfatal cases and postdonation illness. Because of the likelihood of underreporting to the FDA's surveillance systems, these data suggest that the incidence of transfusion-transmitted babesiosis may be increasing. . These data do not include reports of infected donors identified prospectively through antibody assay research trials. BPDRs may include 11 recipient, unit, or donation. Potential implication in transfusion-transmitted disease refers to reports that indicate the safety of a blood component unit that may have been affected (e.g., instances when a blood transfusion recipient received a diagnosis of babesiosis, but the donor could not be contacted for confirmation). Postdonation illness refers to illness in donors who notified the blood collection establishment after donation that they had received a diagnosis of babesiosis. Whether these donors were infected at the time of donation was unknown; all units (not yet transfused) from these donors were withdrawn, and the donors were indefinitely deferred.
Babesia infection should be considered among potential etiologies for otherwise unexplained fever in patients who have recently received blood products. Because of the mobility of donors and transportation of blood products, babesiosis should be considered even beyond geographical regions with naturally occurring disease. As noted in table 2, several donors did not live in areas of endemicity but had traveled to these regions before donating blood.
Patients presented with symptoms (table 2) that were typical of natural infections. Most developed altered mental status, renal failure, or respiratory distress. The interval from blood transfusion to symptom onset was 2.5-7 weeks (table 3 ). An earlier article reported a 1-9-week time frame for transfusiontransmitted babesiosis [17] . These ranges of latency periods contrast with the natural infection incubation time of 2-4 weeks.
With 1 exception, all patients received transfusions from August through December, consistent with the seasonality of Babesia infection. Chronic parasitemia in the donor may have accounted for the 1 case involving a blood transfusion in April.
Implicated donations were identified in all cases; the donors tested positive by peripheral blood smear or immunofluorescence antibody assay. Four donors' samples also tested by PCR had negative results. They may have been convalescent and no longer parasitemic or were PCR negative because of the small sampling volume. All donors were asymptomatic at donation and remembered no tick bite.
Because many babesiosis cases may escape recognition, questioning donors has limited preventive value [17] . Babesia species can survive blood banking procedures, including refrigeration, leukoreduction, and filtration; pathogen transmission through transfusion of RBCs, deglycerolized RBCs, or platelets can occur [1, [18] [19] [20] [21] . Babesia parasites can survive in frozen RBCs, because the glycerol treatment prevents lysis.
In view of the short periods between symptom onset and death (5-17 days) (table 3), examination of a peripheral blood smear (or other testing, depending on availability and the level of clinical suspicion) for possible Babesia species should be considered early in the evaluation of unexplained fever during the first few weeks after transfusions, particularly in asplenic or otherwise immunocompromised patients. Infectious disease consultation may be required to microscopically distinguish Babesia species from Plasmodium organisms.
Although babesiosis is not nationally notifiable, reporting transfusion-transmitted Babesia infections to public health authorities can allow investigators to identify infected donors and interdict remaining units. Investigation of prior donations also allows testing of associated recipients.
Similarly, blood collectors should immediately report postdonation babesiosis to the transfusion facilities to expedite prompt withdrawal of potentially infected unexpired blood components. We remind blood establishments of the requirement to submit fatality and BPDRs to the FDA.
Our data cannot distinguish whether the increase in the numbers of deaths and reports to the BPDR system reflect an increasing incidence of babesiosis and/or improved diagnosis and reporting. State Health Departments (e.g., in New York and Connecticut) have also seen an increase in the number of babesiosis case reports over the past 10 years [22] [23] [24] [25] .
Each year, 15 million recipients receive 114 million transfusions of whole blood or RBCs [26] . Transfusion-transmitted babesiosis appears to be rare, but increased clinician awareness of the possibility of babesiosis in febrile transfusion recipients may facilitate earlier diagnosis and more successful treatment. It will also trigger timely public health investigations to interdict extant infected units and alert other associated recipients, protecting others from this potentially fatal blood-borne pathogen.
Addendum. During final revisions of this article in late September 2008, the FDA received a report of another death associated with transfusion-transmitted babesiosis. An elderly woman in Minnesota died ∼3 weeks after receipt of 2 units of RBCs. One of the donated units' retention segments was positive for Babesia species by serologic testing and PCR.
